Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Common Genetic Polymorphisms Contribute to the Association between Non-Melanoma Skin Cancer and Chronic Lymphocytic Leukemia

Caroline Besson, MDPhD, Amy Moore, Wenting Wu, Nicola J Camp, PhD, Claire Vajdic, Lindsay M. Morton, PhD, Karin E Smedby, MD PhD, Silvia de Sanjose, Tait D Shanafelt, MD, Jerry Brewer, Lydia Zablotska, Eric A. Engels, MD MPH, James R. Cerhan, MD PhD, Susan L Slager, PhD, Jiali Han, Sonja I Berndt, PhD

Blood (2017) 130 (Supplement 1): 1454.

https://doi.org/10.1182/blood.V130.Suppl_1.1454.1454

Published: 2017

Journal Articles

An Effective and Tolerable Chemoimmunotherapy Regimen For Relapsed/Refractory and Very-High Risk Chronic Lymphocytic Leukemia Combining Alemtuzumab With Pentostatin and Low Dose Rituximab

Clive S. Zent, MD, Betsy R LaPlant, MS, Wenting Wu, PhD, Timothy G. Call, MD, Deborah Bowen, CNP, Michael J. Conte, PA-C, George J. Weiner, MD, Thomas E Witzig, MD

Blood (2013) 122 (21): 1641.

https://doi.org/10.1182/blood.V122.21.1641.1641

Published: 2013

Journal Articles

Immune Phenotyping and Naive T Cells as a Predictor of Response to Therapy In Chronic Lymphocytic Leukemia (CLL)

Clive S. Zent, MD, Roshini Abraham, Ph.D., Yi Lin, MDPhD, Michael Gustafson, PhD, Wenting Wu, PhD, Allan Dietz, PhD

Blood (2010) 116 (21): 1362.

https://doi.org/10.1182/blood.V116.21.1362.1362

Published: 2010

Journal Articles

Long Term Follow-up and IWG-MRT Response Assessment for 50 Myelofibrosis (MF) Patients Treated with Thalidomide-Prednisone Based Regimens

Prakash Thapaliya, MBBS, MD, Ayalew Tefferi, MD, Animesh Pardanani, MBBS, PhD, David P. Steensma, MD, John Camoriano, MD, Wenting Wu, Susan Geyer, PhD, Ruben A. Mesa, MD

Blood (2010) 116 (21): 4094.

https://doi.org/10.1182/blood.V116.21.4094.4094

Published: 2010

Journal Articles

DIPSS-Plus: A Refined Dynamic International Prognostic Scoring System (DIPSS) for Primary Myelofibrosis That Incorporates Karyotype, Platelet Count and Transfusion Status

Naseema Gangat, MD, Domenica Caramazza, MD, Rakhee Vaidya, Geeta George, PA, Kebede Begna, MD, Susan Schwager, Daniel L. Van Dyke, PhD, Curtis Hanson, MD, Wenting Wu, PhD, Animesh Pardanani, MBBS, Phd, Francisco Cervantes, MD, Francesco Passamonti, MD, Ayalew Tefferi, MD

Blood (2010) 116 (21): 4104.

https://doi.org/10.1182/blood.V116.21.4104.4104

Published: 2010

Journal Articles

Platelet-derived growth factor (PDGF)–PDGF receptor interaction activates bone marrow–derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch

Wei Ding, Traci R. Knox, Renee C. Tschumper, Wenting Wu, Susan M. Schwager, Justin C. Boysen, Diane F. Jelinek, Neil E. Kay

Blood (2010) 116 (16): 2984–2993.

https://doi.org/10.1182/blood-2010-02-269894

Published: 2010

Includes: Supplemental data

Journal Articles

Phase 1/2 Dose Finding Study of Pomalidomide in Myelofibrosis.

Ruben A. Mesa, MD, Animesh D. Pardanani, MBBS, PhD, Kebede Hussein, MD, Wenting Wu, PhD, Susan Schwager, Mark R. Litzow, MD, William J Hogan, MD, Ayalew Tefferi, MD

Blood (2009) 114 (22): 2911.

https://doi.org/10.1182/blood.V114.22.2911.2911

Published: 2009

Journal Articles

Role of Platelet-Derived Growth Factor On Vascular Endothelial Growth Factor Synthesis by Mesenchymal Stem Cells in Chronic Lymphocytic Leukemia: Implications for Clinical Progression.

Wei Ding, MD, PhD, Traci Knox, Susan Schwager, Charla Secreto, Asish K Ghosh, PhD, Wenting Wu, Neil E. Kay, MD

Blood (2009) 114 (22): 804.

https://doi.org/10.1182/blood.V114.22.804.804

Published: 2009

Journal Articles

Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab

Farrukh T. Awan, Neil E. Kay, Melanie E. Davis, Wenting Wu, Susan M. Geyer, Nelson Leung, Diane F. Jelinek, Renee C. Tschumper, Charla R. Secreto, Thomas S. Lin, Michael R. Grever, Tait D. Shanafelt, Clive S. Zent, Timothy G. Call, Nyla A. Heerema, Gerard Lozanski, John C. Byrd, David M. Lucas

Blood (2009) 113 (3): 535–537.

https://doi.org/10.1182/blood-2008-08-173450

Published: 2009

Journal Articles

Cyclophosphamide Remains An Important Component of Treatment in CLL Patients Receiving Pentostatin and Rituximab Based Chemoimmunotherapy

Neil E. Kay, Wenting Wu, John C. Byrd, MD, Brian Kabat, Diane F. Jelinek, PhD, Clive S. Zent, MD, Timothy Call, Thomas Lin, MD, PhD, Tait Shanafelt

Blood (2008) 112 (11): 43.

https://doi.org/10.1182/blood.V112.11.43.43

Published: 2008

Journal Articles

Mcl-1 as a Possible Predictor of Progression-Free Survival in Previously Untreated Chronic Lymphocytic Leukemia Patients Treated with Pentostatin, Cyclophosphamide and Rituximab.

Farrukh Awan, MD, MS, Neil E. Kay, Melanie Davis, Wenting Wu, Nelson Leung, Diane F. Jelinek, Renee Tschumper, Charla Secreto, Thomas S. Lin, Michael R Grever, MD, Tait Shanafelt, MD, Clive S. Zent, Timothy G. Call, Nyla A. Heerema, PhD, Gerard Lozanski, John C. Byrd, MD, David Lucas, PhD

Blood (2008) 112 (11): 2105.

https://doi.org/10.1182/blood.V112.11.2105.2105

Published: 2008

Journal Articles

Alemtuzumab and Rituximab for Initial Treatment of High Risk, Early Stage Chronic Lymphocytic Leukemia (CLL).

Clive S. Zent, MD, Timothy G. Call, MD, Tait D. Shanafelt, MD, Diane F. Jelinek, PhD, Renee C. Tschumper, Charla R. Secreto, Deborah A. Bowen, RN, Susan M. Geyer, PhD, Brian F. Kabat, Betsy R. LaPlant, Wenting Wu, PhD, Neil E. Kay, MR

Blood (2007) 110 (11): 2050.

https://doi.org/10.1182/blood.V110.11.2050.2050

Published: 2007

Journal Articles

Clinical Evolution to Primary Myelofibrosis - Blast Phase: An International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) Collaborative Retrospective Analysis.

Ruben A. Mesa, MD, Francisco Cervantes, MD, Srdan Verstovsek, MD, PhD, Constantine Tam, MD, Brigitte Dupriez, MD, John Reilly, MD, Giovanni Barosi, MD, Megan Campbell, MS, Wenting Wu, PhD, A. Pardanani, MD, PhD, T. Lasho, Ayalew Tefferi, MD

Blood (2007) 110 (11): 682.

https://doi.org/10.1182/blood.V110.11.682.682

Published: 2007

Journal Articles

Erythropoiesis Stimulating Agents and the Risk of Leukemic Transformation in Primary Myelofibrosis.

Jocelin Huang, MD, Chin-Yang Li, MD, Ruben A. Mesa, MD, Wenting Wu, PhD, Curtis A. Hanson, MD, Animesh D. Pardanani, MD, PhD, Ayalew Tefferi, MD

Blood (2007) 110 (11): 554.

https://doi.org/10.1182/blood.V110.11.554.554

Published: 2007

Journal Articles

Risk Stratification for Survival and Leukemic Transformation in Essential Thrombocythemia: A Single Institutional Study of 605 Patients.

Naseema Gangat, MBBS, Alexandra Wolanskyj, MD, Rebecca F. McClure, MD, Chin Y. Li, MD, Susan M. Schwager, Wenting Wu, PhD, Ayalew Tefferi, MD

Blood (2006) 108 (11): 3599.

https://doi.org/10.1182/blood.V108.11.3599.3599

Published: 2006

Journal Articles

Phase II Study of the Combination of Low-Dose Thalidomide, Prednisone, and Oral Cyclophosphamide (TPC Regimen) in the Treatment of Anemia, Splenomegaly, and Constitutional Symptoms Associated with Myelofibrosis with Myeloid Metaplasia (MMM).

Ruben A. Mesa, MD, Animesh Pardanani, MD, PhD, David P. Steensma, MD, Mark Litzow, MD, William Hogan, MD, Susan Geyer, PhD, Wenting Wu, PhD, Jerome Zeldis, MD, PhD, Ayalew Tefferi, MD

Blood (2006) 108 (11): 2689.

https://doi.org/10.1182/blood.V108.11.2689.2689

Published: 2006

NARROW

Common Genetic Polymorphisms Contribute to the Association between Non-Melanoma Skin Cancer and Chronic Lymphocytic Leukemia

An Effective and Tolerable Chemoimmunotherapy Regimen For Relapsed/Refractory and Very-High Risk Chronic Lymphocytic Leukemia Combining Alemtuzumab With Pentostatin and Low Dose Rituximab

Immune Phenotyping and Naive T Cells as a Predictor of Response to Therapy In Chronic Lymphocytic Leukemia (CLL)

Long Term Follow-up and IWG-MRT Response Assessment for 50 Myelofibrosis (MF) Patients Treated with Thalidomide-Prednisone Based Regimens

DIPSS-Plus: A Refined Dynamic International Prognostic Scoring System (DIPSS) for Primary Myelofibrosis That Incorporates Karyotype, Platelet Count and Transfusion Status

Platelet-derived growth factor (PDGF)–PDGF receptor interaction activates bone marrow–derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch

Phase 1/2 Dose Finding Study of Pomalidomide in Myelofibrosis.

Role of Platelet-Derived Growth Factor On Vascular Endothelial Growth Factor Synthesis by Mesenchymal Stem Cells in Chronic Lymphocytic Leukemia: Implications for Clinical Progression.

Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab

Cyclophosphamide Remains An Important Component of Treatment in CLL Patients Receiving Pentostatin and Rituximab Based Chemoimmunotherapy

Mcl-1 as a Possible Predictor of Progression-Free Survival in Previously Untreated Chronic Lymphocytic Leukemia Patients Treated with Pentostatin, Cyclophosphamide and Rituximab.

Alemtuzumab and Rituximab for Initial Treatment of High Risk, Early Stage Chronic Lymphocytic Leukemia (CLL).

Clinical Evolution to Primary Myelofibrosis - Blast Phase: An International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) Collaborative Retrospective Analysis.

Erythropoiesis Stimulating Agents and the Risk of Leukemic Transformation in Primary Myelofibrosis.

Risk Stratification for Survival and Leukemic Transformation in Essential Thrombocythemia: A Single Institutional Study of 605 Patients.

Phase II Study of the Combination of Low-Dose Thalidomide, Prednisone, and Oral Cyclophosphamide (TPC Regimen) in the Treatment of Anemia, Splenomegaly, and Constitutional Symptoms Associated with Myelofibrosis with Myeloid Metaplasia (MMM).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only